ONCAlert | Upfront Therapy for mRCC

Skin Cancers MORE >>

In an interview with Targeted Oncology, Shlomo Koyfman, MD, the director of head and neck and skin cancer radiation at Cleveland Clinic, provides details about the current treatments for cSCC and how the new KEYNOTE-630 trial could improve practice for oncologists who treat cSCC.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.